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Background: In Denmark, guidelines on low back pain management are currently being implemented; in
association with this, a clinical trial is conducted. A health economic evaluation is carried out alongside the clinical
trial to assess the cost-effectiveness of an extended implementation strategy to increase the general practitioners’
adherence to the guidelines. In addition to usual dissemination, the extended implementation strategy is composed
of visits from a guideline facilitator, stratification tools, and feedback on guideline adherence. The aim of this paper
is to provide the considerations on the design of the health economic evaluation.
Methods/design: The economic evaluation is carried out alongside a cluster randomised controlled trial consisting of
60 general practices in the North Denmark Region. An expected 1,200 patients between the age of 18 and 65 years
with a low back pain diagnosis will be enrolled. The economic evaluation comprises both a cost-effectiveness
analyses and a cost-utility analysis. Effectiveness measures include referral to secondary care, health-related quality
of life measured by EQ-5D-5L, and disability measured by the Roland Morris disability questionnaire. Cost measures
include all relevant additional costs of the extended implementation strategy compared to usual implementation.
The economic evaluation will be performed from both a societal perspective and a health sector perspective with a
12-month time horizon.
Discussion: It is expected that the extended implementation strategy will reduce the number of patients referred to
secondary care. It is hypothesised that the additional upfront cost of extended implementation will be counterbalanced
by improvements in clinical practice and patient-related outcomes, thereby rendering the extended implementation
strategy cost-effective.
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Low back pain is one of the most common musculoskel-
etal disorders worldwide, and it has been estimated that
low back pain affects between 80% and 85% of the gen-
eral population at least once in their lifetime [1]. Conse-
quently, low back pain constitutes a substantial personal
and socioeconomic burden. In Denmark, it has been es-
timated that the 2011 socioeconomic cost due to back
pain amounts to € 1.6 billion [2].
According to a review by Koes et al. [3], there are
international consensus on recommendations for man-
agement of low back pain; these include, among others,
advice to avoid bed rest, use of analgesics, recognition
of psychosocial factors, and reduction of secondary
care consumption. Furthermore, Koes et al. show that
these recommendations have been consistent over the
past decade. On these grounds, Koes et al. conclude
that future efforts should concentrate on the imple-
mentation of guidelines for low back pain management,
as systematic implementation is rare, and therefore, pa-
tients may receive suboptimal treatment [3]. This is in
agreement with a paper by Krismer and van Tulder [4].
In this paper, it is emphasised that health professionals
should follow the issued guidelines to ensure the bene-
ficial treatment effects and reduce the personal and so-
cioeconomic burden of low back pain [4].
In Denmark, the new guidelines on low back pain
management in general practice are largely in agree-
ment with the guidelines evaluated in Koes et al. [3,5].
These guidelines have the potential to improve quality
of care and to save costs by reducing the number of pa-
tients referred to secondary care. Utilising secondary
care resources optimally is essential, as it has been esti-
mated that, currently, 78% of the annual cost of treat-
ment for back pain in Denmark is associated with
secondary care [2].
In this study, it is hypothesised that greater adherence
to the guidelines may improve patient-related outcomes
and, possibly, decrease utilisation of secondary care. The
cost-effectiveness of extending the implementation strat-
egy is, however, unknown.
In association with the publication of the Danish
guidelines, a clinical trial is conducted. Alongside the
clinical trial, an economic evaluation is conducted to
assess the cost-effectiveness of an extended imple-
mentation strategy aimed to increase adherence to the
guidelines, compared to the usual implementation
strategy in Denmark. Further information on, among
others, development of the extended implementation
strategy and recruitment to the clinical trial are pro-
vided elsewhere [6].
The aim of the present paper is to provide the consid-
erations on the design of the economic evaluation car-
ried out alongside the clinical trial.Methods/design
The clinical trial is a cluster randomised controlled trial
where 60 general practices are enrolled from a sample
frame of 191 general practices in the North Denmark
Region. It was initially planned to include a total of
2,700 patients through 100 general practices. All prac-
tices, except practices used for pilot testing (n = 2), were
invited to participate in the clinical trial. Due to fewer
general practices that wished to participate, the number
of practices has been revised to 60 enrolling approxi-
mately 1,200 patients. The clinical trial is due to be com-
pleted July 2015.
This economic evaluation comprises cost-effectiveness
analyses and a cost-utility analysis where the primary out-
comes are incremental cost-effectiveness ratios (ICERs).
The economic evaluation will be performed from both a
societal perspective and a health sector perspective with a
12-month time horizon equal to the follow-up period of
the clinical trial.
Study population
Patients consulting their general practitioner for a new
episode of low back pain diagnosed with ICPC-2 diagno-
sis codes L02, L03, L84, or L86 are eligible for inclusion
[7]. Moreover, the patients must understand Danish and
be aged 18 to 65 years. The general practitioner invites
the patient to participate in the clinical trial and hands
out the first of four questionnaires. In this questionnaire,
the patient is encouraged to give informed consent.
Pregnant women and patients presenting with red flags




In the control group, the general practitioners are intro-
duced to the clinical guidelines (see the succeeding list)
through usual dissemination, consisting of newsletters
and information meetings. The general practitioners will
manage their patients, including referrals to secondary
care, as usual. As an additional feature of usual care, all
general practitioners participating in the clinical trial
have the opportunity to refer low back pain patients for
assessment at the Department of Social Medicine at Aal-
borg University Hospital.
The main recommendations in the clinical guidelines
on management of low back pain in Danish general
practice [5,8] are as follows:
 Guidelines for assessment and referral of patients
with degenerative disorders of the spine
1. Course of treatment should include planned
consultations 2, 4, and 8 weeks after the initial
visit for patients not improving.
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classifying the patient as having nonspecific low
back pain, nerve root pain, or red flags.
3. Anamnesis should include pain intensity, symptoms,
duration of pain, and consumption of analgesics.
4. The general practitioner is to advise the patient
to avoid bed rest and, as far as possible, carry on
normal activities.
5. The general practitioner is to advise the patient
on use of analgesics and may refer to supplement
primary care, e.g. physical training.
6. If no satisfactory progress is reached within
8 weeks, the patient should be referred for
secondary care.Extended implementation strategy
In addition to usual dissemination, general practitioners
allocated to the intervention group will receive further
introduction to the guidelines through three interventions:
(a) visits from a guideline facilitator. When enrolling in the
clinical trial, the general practice receives a visit from a
guideline facilitator, who will inform the practitioner about
the clinical guidelines and discuss management of low
back pain patients. In this clinical trial, five physiothera-
pists with special certification in low back pain assessment
are trained as facilitators. (b) Access to two patient risk-
stratification tools that have been added into the general
practitioners’ electronic medical records: the subgroups for
targeted treatment back screening tool (STarT) and social
risk screening (SOS) questions. STarT divides the patients
into three groups according to their risk of prolonged
symptoms and guide treatment [9]. STarT has been vali-
dated in Danish [10]. SOS has been developed for the clin-
ical trial and addresses barriers for recovery including
occupational factors, disability compensation or pension
claims, and psychosocial factors [6]. Earlier studies have
previously indicated that patients involved in, for instance,
a compensation claim have poor recovery prognosis,
emphasising the importance of identifying these patients
as early as possible in order to initiate proper treatment
[11,12]. In the clinical trial, the SOS stratification tool is
applied to identify patients who are eligible for treatment
at the Department of Social Medicine.
The third component of the intervention is (c) feed-
back on guideline adherence. Throughout their partici-
pation in the clinical trial, the general practitioners will
have contact with their guideline facilitator and, further-
more, have access to quality reports on their treatment
of patients with low back pain compared to other clinics
in the North Denmark Region.
Data collection
When the general practitioner enters one of the ICPC-2
codes into the electronic medical record, a pop-up isactivated. The pop-up is activated at each consultation
concerning low back pain with the patient and collects
data on, among other factors, triage (nonspecific low back
pain, nerve root pain, and red flags), duration of pain,
symptoms, previous episodes of low back pain, supple-
mentary treatment, and referrals to secondary care. In the
intervention group, the two patient risk-stratification tools
STarT and SOS are likewise included in the pop-up.The economic evaluation
Resource consumption and estimation of costs
Costs will be calculated in euros (€) for each participant
in the clinical trial. A summary of the source of re-
sources and corresponding source of unit costs is pro-
vided in Table 1. The economic evaluation is performed
as a within-trial analysis, indicating that only costs and
effects that accumulate within the trial length are included.
Costs are identified and valued as all disease-related direct
costs, e.g. contact with primary and secondary health care
and patient costs, and indirect costs, which include both
absenteeism and presenteeism.
Primary healthcare utilisation will be based on service
fees reimbursed to general practitioners, while secondary
healthcare utilisation will be valued by means of the Da-
nish case-mix system. Furthermore, patient costs, such
as costs of medication and transportation will be esti-
mated. The human capital approach will be applied to
estimate the costs of absenteeism. The impact of esti-
mating these by use of the friction method and of ex-
cluding indirect costs will likewise be investigated
[13,14]. Patient-reported decrease in productivity due to
low back pain is used to estimate presenteeism.
Implementation costs, including costs of pop-up de-
velopment, education of guideline facilitators, and the
ongoing contact between the general practitioners and
the guideline facilitators are to be included. To maintain
a conservative approach to cost estimation, the imple-
mentation costs are not amortised.Effectiveness measures
The number of referrals from primary care to secondary
care within the first 12 weeks following the initial con-
sultation at the general practice is used as one of the ef-
fectiveness measures in the cost-effectiveness analysis.
As previously mentioned, consumption of secondary
care is a potent cost driver. Hence, increasing the pro-
portion of successful treatment courses in primary care
may decrease secondary costs and, subsequently, total
costs. Furthermore, decreasing the number of referrals
may indicate an increased adherence to the clinical
guidelines as well as increased quality of treatment in
primary care, rendering the number of referrals as an
appropriate effectiveness measure.
Table 1 Measurements of resources and costs
Type of
cost








Pop-up and patient in comparison with the
Danish National Health Insurance Service
Registry






The Danish National Patient Registry The Danish National Patient
Registry




Analgesic, NSAIDs, gastric protectors,
tramadol, and antidepressants
Patient, Danish Medicines Agency Danish Medicines Agency
Transportation Travel expenses for the patient Distance between home address
and general practitioner
Mileage allowance according to
the Danish National Tax Board









and guideline facilitator visits
Nord-KAP, guideline facilitator Nord-KAP
Indirect
cost
Absenteeism Absence from work Patient, DREAM Mean wage according
to Statistics Denmark
Presenteeism Reduced productivity at work
due to low back pain
Patient Mean wage according
to Statistics Denmark
DAK-E Danish quality unit of general practice, Nord-KAP quality unit for general practice in the North Denmark Region, DREAM the Danish Register of Sickness
absence and compensation benefits and social transfer payments.
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The patient-related effectiveness measures are among
the most commonly used in low back pain research
[15-17] and are as follows: health-related quality of life
(HRQoL) and disability. HRQoL is estimated using the
EuroQol 5-dimension 5-level (EQ-5D-5L), while disabil-
ity is evaluated by the use of the Roland Morris disability
questionnaire (RDQ; running from 0–23; lower scores
indicate a lower degree of disability).
The patient-related effectiveness measures are captured
through a questionnaire four times during the trial: at
baseline and after 4, 8, and 52 weeks. Furthermore, pain is
rated on a numerical rating scale (scale 0–10; a low score
indicating less pain), while educational and occupational
status, treatment satisfaction, use of medication, presence
of comorbidity, and whether the patient has received
counselling on activity level are recorded.
Health-related quality of life
HRQoL is estimated from EQ-5D-5L. The EQ-5D in-
strument is used to calculate quality-adjusted life-years
(QALYs), which is the most commonly used measure of
HRQoL and is recommended in international guidelines
[18]. The EQ-5D instrument consists of two parts: the
EQ-5D descriptive system and the EQ visual analogue
scale (VAS; scale 0–100; a lower score indicates a lower
health-related quality of life), respectively. The descrip-
tive system measures the patient’s HRQoL at five levels
of severity in five dimensions: mobility, self-care, usualactivities, pain/discomfort, and anxiety/depression. This
yields 3,125 health states, which are converted to a
HRQoL score using the Danish utility weights [19].
The five-level version has been chosen rather than the
three-level version, due to its potentially greater sensitivity
and reliability, though there are currently no Danish utility
weights available for the five-level version [20]. If no
country-specific utility weights are available at the planned
time of analysis and publication, a crosswalk to the existing
Danish EQ-5D-3L utility weights will be performed [21].
The EQ-5D scores and disability scores from each
measurement are used to estimate effectiveness, QALYs,
and disability over the 1-year period of the clinical trial.
QALYs are estimated by multiplying time with the aver-
age HRQoL, rendering QALY a composite measure of
both quantity and quality of life lived [13].
Statistical analysis
Analyses will be conducted according to the principle of
intention-to-treat in comparisons of the two groups,
control and intervention, respectively [22,23]. The eco-
nomic evaluation will use patient-level data on resource
use and effect within the clinical trial period to assess
the cost-effectiveness of the extended implementation
strategy versus usual implementation.
Costs
Cost analyses will include measures of arithmetic means,
between-group differences, and variability of differences,
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will be presented by trial arm, both as a cost per item
and as a total cost for each follow-up during the trial
period.Effectiveness measures
Effectiveness of the intervention will be analysed in
agreement with the CONSORT statement, extended to
cluster randomised trials (see Additional file 1) [24]. Ef-
fectiveness measures applied in the cost-effectiveness
analyses correspond to the clinical end points of the
trial. Statistical analyses of these are described in the
clinical trial protocol [6,23].
The cost-effectiveness analyses will be completed re-
gardless of whether the clinical trial demonstrates a sig-
nificant difference in secondary care referrals or any
clinically relevant changes in disability, as recommended
by Ramsey et al. [23].
Difference in arithmetic mean QALY will be applied
as the effectiveness measure in the cost-utility analysis.
For the EQ-5D-5L index values, measures of central
tendency and dispersion will be presented for both
groups at baseline and after 4, 8, and 52 weeks. These
will be presented along with median values as well as
the 25th and the 75th percentiles, as recommended by
the EuroQol Group [19]. Assessment of outcomes will
be blinded.Missing data
In health economic evaluations alongside clinical trials,
the presence of missing data, other than censoring, is
often to be expected [22,23]. However, due to the ex-
tensive registration of, among others, activities and re-
ferrals in primary care for all Danish citizens in the
Danish National Health Insurance Service Register
[25], data on referrals to secondary care is expected to
be close to complete. Data completeness on patient-
related effectiveness measures is expected to be some-
what lower. Multiple imputations will be carried out if
missing data is considered to be missing at random or
missing completely at random, but not if it is deemed
to be missing not at random [23,26,27].Regression analysis
To adjust for baseline covariates, regression analysis of
cost and QALY will be applied. Included baseline covari-
ates will be: age, gender, history of low back pain epi-
sodes, length of low back pain episode, comorbidity,
pain intensity, disability, and HRQoL (for the QALY re-
gression). Generalised linear models are considered be-
cause cost, as well as QALY, does not follow a Gaussian
distribution [28].Cost-effectiveness
The economic evaluation is conducted as a within-trial
analysis, where the cost-effectiveness will be presented
in terms of ICERs, calculated as the arithmetic mean dif-
ference in cost between the extended implementation
strategy and the usual implementation strategy divided
by the arithmetic mean difference in effect [13,22].
A number of sensitivity analyses are considered to
quantify the level of decision uncertainty, e.g. cost-
effectiveness scatterplots and cost-effectiveness accept-
ability curves. Deterministic sensitivity analyses will be
performed on chosen variables to identify key determi-
nants for the results. For instance, it is anticipated that if
the pop-up systems, i.e. STarT and SOS, were to be im-
plemented in general practice, the costs of implementa-
tion should be amortised over the lifetime of the asset.
On these grounds, the impact of amortising the costs
will be evaluated in a sensitivity analysis to investigate
whether implementation costs might be a key cost
driver. Finally, sensitivity analyses are made for complete
cases and are unadjusted for baseline covariates.
A 5% significance level is set for all models. STATA/
MP 12.1 will be used for statistical analysis.
Ethics
For the clinical trial, the Regional Scientific Ethics
Committee and the Danish Health and Medicines Au-
thority did not find that approval was a necessity. The
clinical trial is registered with the Danish Data Protection
Agency, the Committee of Multipractice Studies in
General Practice, and at ClinicalTrials.gov (NCT01699256).
Further detail on compilation of various consent forms for
participation in the clinical trial is provided in the protocol
for analysis of the effectiveness of the intervention [6].
Discussion
This paper represents the protocol of an economic
evaluation nested in a cluster randomised controlled
trial, which aims to assess the cost-effectiveness of an
extended implementation strategy compared to usual
implementation of low back pain guidelines in general
practice. The demand to provide evidence of value for
money has resulted in an increased number of eco-
nomic evaluations performed alongside clinical trials;
however, there are some difficulties in the design of
these economic evaluations [29]. Following internation-
ally recognised guidelines [23], this protocol serves to
heighten the transparency of the economic evaluation.
Due to the setup of a clinical trial, Ramsey et al. and
O’Sullivan et al. place great importance on identification
of any possible threats, such as recruitment to the study,
protocol-driven utilisation, and enhanced compliance, to
the external validity of the economic evaluation [23,29].
As recruitment to the study is of importance to the
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proach is adopted in this study to allow for variations
across general practices [30], albeit limited to the North
Denmark Region.
Protocol-driven utilisation covers consumed resources
not normally consumed in standard clinical care and are
also often related to compliance, which constitutes a
complex issue in this study. This study aims to enhance
general practitioners’ adherence to the clinical guidelines
by comparing two different strategies of implementation—
usual dissemination and extended implementation,
respectively—with usual dissemination representing the
normal approach to implementation of new guidelines.
Compliance attributed to the intervention may be
impeded, as participation and continuous focus on a
specific area in a clinical trial can induce artificially en-
hanced compliance. Inevitably, this also affects compli-
ance in the usual care branch and can bias the
economic outcomes by possibly overestimating the
costs and effects in the clinical trial relative to a real-
world setting. This necessitates the need to compare
compliance to the clinical guidelines through clinical
practice patterns between general practices enrolled in
the study and those not participating.
In conclusion, it is expected that the extended imple-
mentation strategy will reduce the number of patients
referred for secondary care and improve patient-related
outcomes. It is hypothesised that the additional upfront
cost of extended implementation will be counterba-
lanced by improvements in clinical practice and patient-
related outcomes, thereby rendering the extended imple-
mentation strategy cost-effective.Additional file
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